• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Herpes zoster vaccine not cost-effective for 50 year-old adults

byMoises GallegosandSai Folmsbee
September 7, 2015
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. From a model, the incremental cost-effectiveness ratio between Herpes zoster vaccination and no vaccination at age 50 years was over $300,000 per QALY.

2. At a willingness to pay threshold of $100,000 per QALY, the probability that vaccination would be cost-effective was only 3%.

Evidence Rating Level: 2 (Good)

Study Rundown: Herpes zoster (HZ) affects nearly 1 million Americans yearly, with post-herpetic neuralgia (PHN) occurring in up to 30% of patients. Studies have shown that vaccination can reduce incidence of HZ and PHN in persons aged 60 years or older, but that effectiveness decreases over time. In 2011, a live vaccine was licensed for adults aged 50-59, but its overall value is largely unknown. This study sought to expand cost-effectiveness models for the HZ vaccine to include considerations for vaccination at age 50. For every 1000 persons, the model predicted that 25 cases of HZ and 1 case of PHN would be prevented. The incremental cost for vaccination versus no vaccination for adults aged 50 in the U.S. would be over $600 million. Strengths of the study included use of a previously established simulation model and inclusion of U.S. based studies for epidemiology, effectiveness, and cost, but this study is also limited by the lack of long-term vaccine effectiveness data. Overall, with decreased incidence of HZ and PHN in persons aged less than 60 years old and a decreasing efficacy of vaccinations over time, earlier vaccination is likely not cost-effective.

Click to read the study, published today in The Annals of Internal Medicine

Relevant Reading: CDC Update on Recommendations for Use of Herpes Zoster Vaccine

In-Depth [decision model]: This study utilized a previously established Markov decision model with updated inputs for vaccine related data in the age group 50-59. Utility decrements were assigned for PHN and serious vaccine reactions based on previously derived data. Costs were based on vaccine, administration, and lost patient wages secondary to complications. If the entire U.S. population of persons aged 50 years old in 2013 were vaccinated, 112,652 cases of HZ and 4504 cases of PHN could be avoided, with an incremental cost of $613 million dollars over no vaccination, for an incremental cost-effectiveness ratio (ICER) of $323,456 per QALY. In 10,000 iterations, the mean ICER was $500,754 per QALY (95%CI $93,510 to $1,691,211), with a median of $362,123. Vaccination at age 59 years of age had the highest effectiveness, the lowest cost, and ICER of $113,121 per QALY. If efficacy remained constant for 10 years before beginning to decrease, the ICER would improve to $14,555 per QALY.

RELATED REPORTS

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Shingles (Herpes Zoster)vaccine
Previous Post

High schoolers use e-cigarettes to vaporize cannabis

Next Post

2 Minute Medicine Rewind August 30 – September 6, 2015

RelatedReports

Clinical practice guidelines linked to improved bronchiolitis outcomes
Infectious Disease

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

May 13, 2022
Preterm infants responsive to PCV13 vaccine
Infectious Disease

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

May 10, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

April 12, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

AD26.COV2.S vaccine provides protection against Covid-19

March 7, 2022
Next Post
Food environment associated with gestational diabetes

2 Minute Medicine Rewind August 30 – September 6, 2015

Glioblastoma phenotypes identified on MRI predict molecular behavior

Glioblastoma phenotypes identified on MRI predict molecular behavior

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.